

Substitute for form 1449B-PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/847,525
Filing Date	May 1, 2001
First Named Inventor	Ming Fai CHAN, et al.
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	NB 2016.00

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
NB	1	HASKO, Gyorgy et al. "Inosine Inhibits Inflammatory Cytokine Production by a Posttranscriptional Mechanism and Protects Against Endotoxin-Induced Shock" (January 15, 2000), The Journal of Immunology, 164(2):1013-1019.	
	2		
	3		
	4		
	5		
	6		
	7		
	8		
	9		
	10		
	11		
	12		
	13		
	14		
	15		
	16		
	17		
	18		
	19		
	20		
	21		
	22		
	23		
	24		
	25		
	26		

RECEIVED

OCT 07 2002

TECH CENTER 1600/2000

Examiner's  
Signature

Mark Berch

Date  
Considered

11/7/02

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT(S)' INFORMATION DISCLOSURE  
STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.

126745201600

SERIAL NO.

09/847,525

INVENTOR

Ming Fai CHAN et al.

FILING DATE

May 1, 2001

GROUP ART UNIT

Not Yet Assigned

## REFERENCE DESIGNATION

## U.S. PATENT DOCUMENTS

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	NAME	Class	Subclass	Filing Date If Appropriate
<i>MB</i>	A1	3,993,779	11/23/1976	Dünnenberger et al.			
<i>MB</i>	A2	4,031,248	06/21/1977	Schellenbaum et al.			
<i>MB</i>	A3	5,085,983	02/04/1992	Scanlon			
<i>MB</i>	A4	5,399,346	03/21/1995	Anderson et al.			
<i>MB</i>	A5	5,801,242	09/01/1998	Randall et al.			
<i>MB</i>	A6	5,985,854	11/16/1999	Kozak			
<i>MB</i>	A7	6,150,146	11/21/2000	Hamade et al.			

## OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.)

<i>MB</i>	C1	Bansal, S.K. and Gessner, T. <i>A Unified Method for the Assay of Uridine Diphosphoglucuronyl-transferase Activities Toward Various Aglycones Using Uridine Diphospho[U-<sup>14</sup>C] Glucuronic Acid</i> (1980) <i>Anal. Biochem.</i> 109:321-329.
<i>MB</i>	C2	Barlow, J. et al. <i>Antibiotic Resistance Sized Up</i> (March 2001) <i>Nature Biotechnology</i> 19:217.
<i>MB</i>	C3	Bush, K. <i>Beta-Lactamase Inhibitors from Laboratory to Clinic</i> (January 1988) <i>Clinical Microbiol. Rev.</i> 1(1): 109-123.
<i>MB</i>	C4	de Groot, F.M.H. et al. <i>Synthesis and Biological Evaluation of 2'-Carbamate-Linked and 2'-Carbonate-Linked Prodrugs of Paclitaxel: Selective Activation by the Tumor-Associated Protease Plasmin</i> (2000) <i>J. Med. Chem.</i> 43:3093-3102.
<i>MB</i>	C5	Kashani-Sabet, M. et al. <i>Detection of Drug Resistance in Human Tumors by in Vitro Enzymatic Amplification</i> (October 15, 1988) <i>Canc. Res.</i> 48(20):5775-5778.
<i>MB</i>	C6	Maher et al. <i>The Sensitive Detection of Fluorescently Labelled PCR Products Using an Automated Detection System</i> (1995) <i>Mol. Cell. Probes</i> 9:265-276.
<i>MB</i>	C7	Maranan, M. C. et al. <i>Antimicrobial Resistance in Staphylococci: Epidemiology, Molecular Mechanisms and Clinical Relevance</i> (December 1997) <i>Antimicrobial Resistance</i> 11(4):813-849.
<i>MB</i>	C8	Medeiros, A. A. <i>Beta-Lactamases</i> (1984) <i>Br. Med. Bull.</i> 40:18-27.
<i>MB</i>	C9	Mobashery, S. et al. <i>Reactions of Escherichia coli TEM Beta-Lactamase with Cephalothin and with C<sub>10</sub>-Dipeptidyl Cephalosporin Esters</i> (June 15, 1986) <i>The Journal of Biological Chemistry</i> 261(17):7879-7885.
<i>MB</i>	C10	Mobashery, S. et al. <i>Conscripting Beta-Lactamase for Use in Drug Delivery, Synthesis and Biological Activity of a Cephalosporin C<sub>10</sub>-Ester of an Antibiotic Dipeptide</i> (1986) <i>J. Am. Chem. Soc.</i> 108:1686-1688.
<i>MB</i>	C11	Murray, B. E. <i>Antibiotic Resistance</i> (1997) <i>Adv. Int. Med.</i> 42:339-367.
<i>MB</i>	C12	Novak, R. et al. <i>Emergence of Vancomycin Tolerance in Streptococcus Pneumoniae</i> (June 10, 1999) <i>Nature</i> 399:590-593.
<i>MB</i>	C13	Vrudhula, V. M. <i>Cephalosporin Derivatives of Doxorubicin as Prodrugs for Activation by Monoclonal Antibody-Beta-Lactamase Conjugates</i> (1995) <i>J. Med. Chem.</i> 38:1380-1385.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).